Market Research Logo

Cat Allergy - Pipeline Review, H1 2015


Attention: There is an updated edition available for this report.

Cat Allergy - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Cat Allergy - Pipeline Review, H1 2015’, provides an overview of the Cat Allergy’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Cat Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cat Allergy and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Cat Allergy
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Cat Allergy and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Cat Allergy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Cat Allergy pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Cat Allergy
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Cat Allergy pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Cat Allergy Overview
Therapeutics Development
Pipeline Products for Cat Allergy - Overview
Pipeline Products for Cat Allergy - Comparative Analysis
Cat Allergy - Therapeutics under Development by Companies
Cat Allergy - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Cat Allergy - Products under Development by Companies
Cat Allergy - Companies Involved in Therapeutics Development
ALK-Abello A/S
Amgen Inc.
Biomay AG
Circassia Pharmaceuticals plc
Laboratorios LETI S.L.
Cat Allergy - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ALK Recombinant Cat Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Allergen for Cat Allergy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AMG-157 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BM-36 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cat Epithelial Allergenic Extract - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cat-SPIRE - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cat Allergy - Recent Pipeline Updates
Cat Allergy - Dormant Projects
Cat Allergy - Discontinued Products
Cat Allergy - Product Development Milestones
Featured News & Press Releases
Jan 08, 2015: Circassia Completes Recruitment for Cat Allergy Treatment Pivotal Phase III Study
Feb 25, 2013: Circassia’s ToleroMune Cat Allergy Treatment Maintains Symptom Improvement Two Years After Start Of Short-course Therapy
Oct 04, 2012: Circassia Initiates Pivotal Phase III ToleroMune Trial In Cat Allergen-induced Rhinoconjunctivitis
Sep 27, 2012: Circassia Announces Publication Of ToleroMune Cat Allergy Treatment Clinical Results In Journal of Allergy And Clinical Immunology
Jun 13, 2011: Circassia's Rapid Four-Dose ToleroMune Treatment Maintains Significant Reduction In Allergy Symptoms During 12-Month Follow-up
Feb 01, 2011: Circassia's ToleroMune T-cell Vaccine Achieves Significant Reduction In Allergy Symptoms In Key Phase II Clinical Study
Sep 30, 2010: Circassia Initiates Phase II Trials Of Novel Grass And Ragweed Allergy Therapies And Advances Phase III Plans For Cat Allergy T-cell Vaccine
Jan 19, 2010: Circassia Extends Its Clinical-Stage Portfolio With Phase II Trials of T-cell Vaccines Against House Dust Mite And Cat Allergies
Nov 20, 2009: Circassia Announces Successful Results From Phase II Clinical Study Of ToleroMune Cat Allergy Therapy
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Cat Allergy, H1 2015
Number of Products under Development for Cat Allergy - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Cat Allergy - Pipeline by ALK-Abello A/S, H1 2015
Cat Allergy - Pipeline by Amgen Inc., H1 2015
Cat Allergy - Pipeline by Biomay AG, H1 2015
Cat Allergy - Pipeline by Circassia Pharmaceuticals plc, H1 2015
Cat Allergy - Pipeline by Laboratorios LETI S.L., H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Cat Allergy Therapeutics - Recent Pipeline Updates, H1 2015
Cat Allergy - Dormant Projects, H1 2015
Cat Allergy - Discontinued Products, H1 2015
List of Figures
Number of Products under Development for Cat Allergy, H1 2015
Number of Products under Development for Cat Allergy - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report